Head of Assay Development and Screening Platform
HelmholtzZentrum München
German Research Center for Environmental Health (GmbH)
Institute of Molecular Toxicology and Pharmacology
Germany
http://www.helmholtz-muenchen.de/adsp
Dr. Kamyar Hadian is currently the Head of the ‘Assay Development and Screening Platform’ at the HelmholtzZentrum München in Munich/Germany. He has in-depth experience in designing biochemical High-Throughput Screening (HTS) assays as well as phenotypic cell-based assays for High-Content Screening (HCS) in various disease areas including Cancer, Diabetes, Virology, Immunology and more. His current research focus is targeting protein-protein interactions in various cellular signaling processes. Before that, Kamyar studied Biology at the Technical University of Munich (TUM) and gained his PhD at the HelmholtzZentrum München/Ludwig Maximilians University (LMU) in the field of Virology (HIV research). After a short PostDoc period in the field of NF-kB signaling, he was appointed the Head of ‘Assay Development and Screening Platform’ at the HelmholtzZentrum München.
